



Terapet SA together with their R&D partners are awarded EUR 700'000 through Eurostars Program (E!114620 ACCELERATE) funded by the EUREKA countries and European Union and CHF 767'737 through Innosuisse Innovation Project (45198.1 IP-LS) by Innosuisse – Swiss Innovation Agency.

Geneva, January 1st, 2021 Terapet SA, a privately held Swiss MedTech company developing innovative solutions for a safer, more precise, and time-saving proton therapy for cancer treatment, announced today the combined successful awards of a total of about CHF 1'530'000 non-dilutive funds. The combined funding supports the development of Terapet's first full-scale prototype to be installed for clinical validation and for building two strong consortia between Terapet and world class research institutes: one with CERN, funded through the Innosuisse Innovation Project, and one with Karolinska Institute and the first Nordic Proton Therapy facility, Skandion Clinic, funded through the Eurostars Program.

Both research and development collaborations will officially start on 01.02.2021 and last for the coming 3 years. All the research parties in the consortium are fully funded.

About Proton Therapy

Proton beam therapy is an advanced treatment method for cancer and other tumor diseases. Compared to conventional radiotherapy with x-rays, proton therapy has the advantage that healthy tissue surrounding the tumor receives less dose. This is due to the fact that protons stop at a certain depth inside the patient, delivering a very high dose just before they stop (the Bragg peak). The dose "behind" the tumor is close to zero. The lower dose to healthy tissue is particularly important when treating children since they have a long-life expectancy after treatment. It also makes it superior for treating critical cancer types (e.g., brain tumors, prostate cancers) with tumors that are very close to critical organs, e.g., brain, spine, optical nerves, sensitive nerves etc.

About Eurostars (E!114620 ACCELERATE)

[The Eurostars program](#) is a funding and support program, aimed at R&D-performing SMEs that wish to exploit the benefits that come with international collaboration. Eurostars applications pass through a highly competitive selection process, being scrutinized by a panel of international research and business experts, to ensure that only the best business ideas and strongest partnerships get the support they need.

Terapet together with their clinical partners, ranked **2 out of 500** eligible projects across Europe by European Commission, receives a total of € 700,000 non-dilutive grant financed by [Innosuisse](#), the Swiss Innovation Agency and [Vinnova](#), the Swedish Innovation Agency. [News](#) on Venturelab.

About Innosuisse (45198.1 IP-LS)

[Innosuisse](#) is the Swiss Innovation Promotion Agency. It is a federal entity whose role is to promote science-based innovation in the interests of industry and society in Switzerland.

Innosuisse has been supporting Terapet SA since the very start of the project: Start-up training courses, Initial Coach Program, Core Coach Program, Mentoring as well as the Innosuisse Innovation Cheque for the initial collaboration with CERN. Innosuisse has been a crucial partner who has truly helped Terapet to transform the idea to a real company.

About CERN

[CERN](#), the European Organization for Nuclear Research, is one of the world's largest and most respected centers for scientific research. CERN's main function is to provide the particle accelerators and other infrastructure needed for high-energy physics research – as a result, numerous experiments have been constructed at CERN through international collaborations.

CERN has long been involved in the development of state-of-the-art detector technology - which has found applications beyond high-energy physics in the field of proton therapy. This is a unique opportunity for Terapet to further advance their core technologies with CERN's support, in order to scale up to the full-scale prototype to be ready for clinical validation.

Two of the co-founders are former CERN physicists with more than 10 years' experience from CERN.

About Karolinska Institute

The Nobel Prize-awarding [Karolinska Institute](#) in Stockholm, founded in 1810, is Sweden's only university with a core focus on biomedical sciences and ranks as one of the world's leading medical universities, thanks to its high-quality research, which accounts for 40% of all medical research in Sweden.

Karolinska will provide established physics models to quantify and adapt radiotherapy dosages, which will be applied to proton therapy, as well as the clinical expertise needed for the first prototype solution to be adoptable in the general clinical practice.

About Skandion Clinic

The [Skandion Clinic](#) in Uppsala, Sweden, is the first clinic in the Nordic region to offer proton radiation treatments and is jointly run by seven Swedish county councils. The clinic opened in 2015, currently treating ~300 patients every year.

Skandion will act as clinical partner, providing the use of a proton therapy facility and key information on usability from a clinical and practical perspective.

Company Contacts:

Terapet SA
Avenue de Sécheron 15
CH-1202 Geneva, Switzerland
www.terapet.ch
info@terapet.ch

Founders:

Dr. Christina Vallgren
CEO

Dr. Marcus Palm
CTO

Prof. Raymond Miralbell
CSO